ASH Annual Meeting : Episode 5

Commentary

Video

Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma

Author(s):

Robert M. Rifkin, MD, FACP

Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.

Robert M. Rifkin, MD, FACP, medical oncologist, hematologist, Rocky Mountain Cancer Centers, discusses overall survival analysis and efficacy outcomes from the phase 3 Dreamm-7 trial (NCT04246047) in patients with relapsed/refractory multiple myeloma. Rifkin and colleagues shared this data in a presentation at the 2024 ASH Annual Meeting.

Related Videos
John M. Burke, MD
Eunice S. Wang, MD
Rachel E. Rau, MD
Wade T. Iams, MD
Andrew Kuykendall, MD
Timothy S. Fenske, MD, MS
Dasom (Caroline) Lee, MD
Christina Poh, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
December 11th 2024

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

ASH Annual Meeting | Image Credit: ©alionaprof – stock.adobe.com
December 10th 2024

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR

Chronic Lymphocytic Leukemia | © LAZLO- stock.adobe.com
December 10th 2024

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL